$1.90 Aveaniceweekend, page-4

Number one Management
Second reason DEP not even into phase 3. Phase 3 trials are the proof. DEP only extends an already licensed drug. New drugs coming on line all the time with competing technology.
Third reason our current market cap already has a lot of potential priced in already for DEP.
Fourth reason Vivagel sales disappointing.
And lastly CSL has a niche.

just my opinions.

This week another Bio i'm in announced successful phase 2 trial results to treat STAPH and MRSA, two days after announcement SP back below pre announcement SP . Figure that one out..